Education
About Us
Working with TipRanks
Follow Us
Kadimastem Ltd. (IL:KDST)
:KDST
KDST Stock Chart & Stats
Day’s Range― - ―
52-Week Range515.00 - 2,797.00
Previous CloseN/A
Volume54.68K
Average Volume (3M)8.31K
Market Cap
113.06M
Enterprise Value374.57M
Total Cash (Recent Filing)2.06M
Total Debt (Recent Filing)7.37M
Price to Earnings (P/E)―
Beta1.03
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding4,509,874
10 Day Avg. Volume6,665
30 Day Avg. Volume8,315
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)1.15K
Price to Sales (P/S)0.00
P/FCF Ratio-18.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kadimastem News
KDST FAQ
What was Kadimastem Ltd.’s price range in the past 12 months?
Kadimastem Ltd. lowest stock price was 515.00 and its highest was 2797.00 in the past 12 months.
What is Kadimastem Ltd.’s market cap?
Kadimastem Ltd.’s market cap is 113.06M.
When is Kadimastem Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kadimastem Ltd.’s earnings last quarter?
Currently, no data Available
Is Kadimastem Ltd. overvalued?
According to Wall Street analysts Kadimastem Ltd.’s price is currently Overvalued.
Does Kadimastem Ltd. pay dividends?
Kadimastem Ltd. does not currently pay dividends.
What is Kadimastem Ltd.’s EPS estimate?
Kadimastem Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kadimastem Ltd. have?
Kadimastem Ltd. has 4,509,874 shares outstanding.
What happened to Kadimastem Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kadimastem Ltd.?
Currently, no hedge funds are holding shares in IL:KDST
Company Description
Kadimastem Ltd.
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.